2024年的亮点:超越脂质:在APOE4相关的阿尔茨海默病中免疫功能障碍
Isabella McEwan1,2, Shannon Thomson1,2, Jasmeen K Issar2,3
1Neurodegeneration and Precision Medicine Research Group, Westmead Institute for Medical Research, Westmead, NSW, Australia.
Immunology and cell biology
|April 30, 2025
概括
阿尔茨海默病 (AD) 风险基因阿波利波蛋白E ε4 (APOE4) 与免疫系统问题和炎症有关. 这可能会导致免疫细胞破坏血脑屏障,导致大脑炎症和AD.
科学领域:
- 神经免疫学 神经免疫学
- 阿尔茨海默氏症疾病的遗传学
背景情况:
- 无脂蛋白E ε4 (APOE4) 基因是晚发性阿尔茨海默病 (AD) 的主要遗传风险因素.
- 周围免疫失调和慢性炎症越来越多地被认为是AD病原体的贡献者.
研究的目的:
- 探索APOE4遗传变体与外周免疫系统功能障碍之间的联系.
- 通过破坏血脑屏障 (BBB) 来研究APOE4相关炎症有助于AD发展的假设.
主要方法:
- 对APOE4,外围免疫和炎症现有研究结果的综述.
- 讨论涉及免疫细胞透和神经炎症的拟议机制.
主要成果:
- 有证据表明,APOE4基因型与外周免疫失调之间存在强烈的关联.
- APOE4可能会促进慢性炎症,可能会削弱BBB.
结论:
- 与APOE4相关的外周炎症是AD的潜在驱动因素.
- 通过受损的BBB透免疫细胞可能会启动神经炎症,神经退行和AD病理.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128